191 related articles for article (PubMed ID: 19779714)
1. Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties.
Verma B; Hawkins OE; Neethling FA; Caseltine SL; Largo SR; Hildebrand WH; Weidanz JA
Cancer Immunol Immunother; 2010 Apr; 59(4):563-73. PubMed ID: 19779714
[TBL] [Abstract][Full Text] [Related]
2. TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models.
Verma B; Neethling FA; Caseltine S; Fabrizio G; Largo S; Duty JA; Tabaczewski P; Weidanz JA
J Immunol; 2010 Feb; 184(4):2156-65. PubMed ID: 20065111
[TBL] [Abstract][Full Text] [Related]
3. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death.
Wittman VP; Woodburn D; Nguyen T; Neethling FA; Wright S; Weidanz JA
J Immunol; 2006 Sep; 177(6):4187-95. PubMed ID: 16951384
[TBL] [Abstract][Full Text] [Related]
4. Assessing vaccine potency using TCRmimic antibodies.
Neethling FA; Ramakrishna V; Keler T; Buchli R; Woodburn T; Weidanz JA
Vaccine; 2008 Jun; 26(25):3092-102. PubMed ID: 18353510
[TBL] [Abstract][Full Text] [Related]
5. Development and implementation of a direct detection, quantitation and validation system for class I MHC self-peptide epitopes.
Weidanz JA; Piazza P; Hickman-Miller H; Woodburn D; Nguyen T; Wahl A; Neethling F; Chiriva-Internati M; Rinaldo CR; Hildebrand WH
J Immunol Methods; 2007 Jan; 318(1-2):47-58. PubMed ID: 17134715
[TBL] [Abstract][Full Text] [Related]
6. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies.
Epel M; Carmi I; Soueid-Baumgarten S; Oh S; Bera T; Pastan I; Berzofsky J; Reiter Y
Eur J Immunol; 2008 Jun; 38(6):1706-20. PubMed ID: 18446790
[TBL] [Abstract][Full Text] [Related]
7. ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.
Sinnathamby G; Zerfass J; Hafner J; Block P; Nickens Z; Hobeika A; Secord AA; Lyerly HK; Morse MA; Philip R
Clin Exp Immunol; 2011 Mar; 163(3):324-32. PubMed ID: 21175594
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.
Jain R; Rawat A; Verma B; Markiewski MM; Weidanz JA
J Natl Cancer Inst; 2013 Feb; 105(3):202-18. PubMed ID: 23300219
[TBL] [Abstract][Full Text] [Related]
9. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
[TBL] [Abstract][Full Text] [Related]
10. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
Cohen CJ; Hoffmann N; Farago M; Hoogenboom HR; Eisenbach L; Reiter Y
Cancer Res; 2002 Oct; 62(20):5835-44. PubMed ID: 12384546
[TBL] [Abstract][Full Text] [Related]
11. Opportunities and challenges for TCR mimic antibodies in cancer therapy.
Chang AY; Gejman RS; Brea EJ; Oh CY; Mathias MD; Pankov D; Casey E; Dao T; Scheinberg DA
Expert Opin Biol Ther; 2016 Aug; 16(8):979-87. PubMed ID: 27094818
[TBL] [Abstract][Full Text] [Related]
12. Novel immunodominant epitopes derived from MAGE-A3 and its significance in serological diagnosis of gastric cancer.
Shen X; Jin J; Ding Y; Wang P; Wang A; Xiao D; Xue X; Zhu S; Zhang L; Zhu G
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1529-38. PubMed ID: 23842851
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
14. Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells.
Oh S; Terabe M; Pendleton CD; Bhattacharyya A; Bera TK; Epel M; Reiter Y; Phillips J; Linehan WM; Kasten-Sportes C; Pastan I; Berzofsky JA
Cancer Res; 2004 Apr; 64(7):2610-8. PubMed ID: 15059918
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive mutagenesis identifies the peptide repertoire of a p53 T-cell receptor mimic antibody that displays no toxicity in mice transgenic for human HLA-A*0201.
Trenevska I; Anderson AP; Bentley C; Hassanali T; Wiblin S; Maguire S; Pezzella F; Banham AH; Li D
PLoS One; 2021; 16(4):e0249967. PubMed ID: 33836029
[TBL] [Abstract][Full Text] [Related]
16. Identification of Hydroxysteroid (17β) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomas.
Visus C; Ito D; Dhir R; Szczepanski MJ; Chang YJ; Latimer JJ; Grant SG; DeLeo AB
Cancer Immunol Immunother; 2011 Jul; 60(7):919-29. PubMed ID: 21409596
[TBL] [Abstract][Full Text] [Related]
17. Engineering chimeric human and mouse major histocompatibility complex (MHC) class I tetramers for the production of T-cell receptor (TCR) mimic antibodies.
Li D; Bentley C; Yates J; Salimi M; Greig J; Wiblin S; Hassanali T; Banham AH
PLoS One; 2017; 12(4):e0176642. PubMed ID: 28448627
[TBL] [Abstract][Full Text] [Related]
18. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
[TBL] [Abstract][Full Text] [Related]
19. Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1.
Wang W; Epler J; Salazar LG; Riddell SR
Cancer Res; 2006 Jul; 66(13):6826-33. PubMed ID: 16818660
[TBL] [Abstract][Full Text] [Related]
20. Shared fine specificity between T-cell receptors and an antibody recognizing a peptide/major histocompatibility class I complex.
Stryhn A; Andersen PS; Pedersen LO; Svejgaard A; Holm A; Thorpe CJ; Fugger L; Buus S; Engberg J
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10338-42. PubMed ID: 8816801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
